Latest news with #hemoglobin
Health Line
16-07-2025
- Health
- Health Line
How to Raise Your Hemoglobin Count
Key takeaways Increasing your intake of iron-rich foods like liver, shellfish, spinach, and beans can help boost hemoglobin production. Taking iron supplements may be necessary to significantly raise hemoglobin levels, but it's important to work with your doctor to determine a safe dosage to avoid potential side effects. To maximize iron absorption, consume vitamin C-rich foods along with iron sources and avoid calcium-rich foods or supplements close to iron intake. Read on to learn about how to raise your hemoglobin and what things to consider. What's a low hemoglobin count? Hemoglobin is a protein in your red blood cells that carries oxygen to the rest of your body. It also transports carbon dioxide out of your cells and back to your lungs to be exhaled. The Mayo Clinic defines low hemoglobin counts as anything below 13.5 grams per deciliter in men or 12 grams per deciliter in women. Many things can cause low hemoglobin levels, such as: iron deficiency anemia pregnancy liver problems urinary tract infections In addition, some people have naturally low hemoglobin counts without any underlying cause. Others have low hemoglobin, but never have any symptoms. Eat foods high in iron and folate Iron plays an important role in hemoglobin production. A protein called transferrin binds to iron and transports it throughout the body. This helps your body make red blood cells, which contain hemoglobin. The first step toward raising your hemoglobin level on your own is to start eating more iron. Foods that are high in iron include: liver and organ meats shellfish beef broccoli kale spinach green beans cabbage beans and lentils tofu baked potatoes fortified cereals and enriched bread Folate is a B vitamin that your body uses to produce heme, the part of your red blood cells that contains hemoglobin. Without enough folate, your red blood cells can't mature. This can lead to folate deficiency anemia and low hemoglobin levels. You can add folate to your diet by eating more: beef spinach black-eyed peas avocado lettuce rice kidney beans peanuts Take iron supplements If you need to raise your hemoglobin level by a lot, you may need to take oral iron supplements. However, too much iron can cause a condition called hemochromatosis. This can lead to liver diseases such as cirrhosis, and other side effects, such as constipation, nausea, and vomiting. Work with your doctor to figure out a safe dose, and avoid taking more than 25 milligrams (mg) at one time. The National Institutes of Health's Office of Dietary Supplements recommends that men get up to 8 mg of iron per day, while women should get up to 18 mg per day. If you're pregnant, you should aim for up to 27 mg a day. You should start noticing a difference in your iron level after about a week to a month, depending on your underlying condition that's causing low hemoglobin. Iron supplements should always be kept carefully out of reach of children. If your child needs an iron supplement, make sure you choose one that's safe for children. Children have a lower blood volume, which makes them much more vulnerable to iron poisoning. If your child accidentally takes an iron supplement, call your doctor immediately. Maximize iron absorption Whether you increase your iron intake through food or supplements, it's also important to make sure your body can easily process the extra iron you put into it. Certain things can either increase or decrease the amount of iron your body absorbs. Things that increase iron absorption When you eat something high in iron or take an iron supplement, try eating foods rich in vitamin C or take a supplement at the same time. Vitamin C may help to increase the amount of iron your body absorbs. Try squeezing some fresh lemon over iron rich foods to increase absorption. Foods high in vitamin C include: citrus strawberries dark, leafy greens Vitamin A and beta-carotene, which helps your body produce vitamin A, can also help your body absorb more iron. You can find vitamin A in animal food sources, such as fish and liver. Beta-carotene is usually found in red, yellow, and orange fruits and vegetables, such as: carrots winter squash sweet potatoes mangos You can also take vitamin A supplements, but make sure you work closely with your doctor to figure out a safe dose. Too much vitamin A can lead to a potentially serious condition called hypervitaminosis A. Things that decrease iron absorption Calcium from both supplements and food sources can make it harder for your body to absorb iron. However, it's important that you don't completely eliminate calcium because it's an essential nutrient. Just avoid calcium supplements and try not to eat calcium-rich foods right before or after taking an iron supplement. Foods high in calcium include: dairy soybeans seeds figs Phytic acid can also reduce your body's absorption of iron, especially if you don't eat meat. However, it only affects iron absorption during a single meal, not throughout the day. If you don't eat meat, try to avoid eating foods high in phytic acid with iron-rich foods. Foods high in phytic acid include: walnuts Brazil nuts sesame seeds Keep in mind that, like calcium, phytic acid is an essential nutrient that shouldn't be completely removed from your diet. When to see a doctor Some cases of low hemoglobin can't be fixed through diet and supplements alone. Contact your doctor if you have any of the following symptoms while trying to raise your hemoglobin level: pale skin and gums fatigue and muscle weakness a fast or irregular heartbeat frequent headaches frequent or unexplained bruising The bottom line Depending on the underlying cause and the changes you make, it can take anywhere from a few weeks to almost a year to raise your hemoglobin count.
Globe and Mail
07-07-2025
- Health
- Globe and Mail
Sickle Cell Disease Drugs Market 2034: Clinical Trials, Prevalence, EMA, PDMA, FDA Approvals, Medication, Statistics, NICE Approval.Revenue and Companies by DelveInsight
Sickle Cell Disease companies working in the treatment market are Cellectis, Sana Biotechnology, Global Blood Therapeutics, Inc., CSL Behring, Pfizer, Aruvant Sciences, Graphite Bio, Novartis, Agios Pharmaceuticals, Forma therapeutics, Vertex Pharmaceuticals, Global Blood Therapeutics, Inc., Alfasigma, Novo Nordisk, bluebird bio, ExCellThera, Gamida Cell, KM Biologics/Takeda, Editas Medicine, and others. Sickle Cell Disease Market Summary In 2023, the Sickle Cell Disease (SCD) market across the 6MM was valued at approximately USD 650 million, with the United States dominating at ~USD 603 million (92% share), followed by France and the UK. SCD is a hereditary blood disorder caused by mutations in the HBB gene, resulting in abnormal hemoglobin (HbS) that distorts red blood cells into a sickle shape. These rigid cells obstruct microvasculature, triggering vaso-occlusive crises, anemia, acute chest syndrome, stroke, organ damage, and heightened infection risk, severely impacting patient quality of life and survival. Historically, management relied on NSAIDs, transfusions, chelators, and supportive care, with hydroxyurea (DROXIA) being the primary disease-modifying agent for decades. Recent approvals of ENDARI (L-glutamine), ADAKVEO (crizanlizumab), and OXBRYTA (voxelotor) have expanded options, though challenges in adherence and reimbursement persist. New approvals like CASGEVY (exa-cel) and LYFGENIA (lovo-cel) are expected to drive market growth, alongside pipeline candidates such as EDIT-301, Mitapivat, Inclacumab, and Osivelotor. Despite advances, delays in diagnosis, economic burden, and complications continue to constrain outcomes. Multidisciplinary care, genetic counseling, early intervention, and patient education are critical, while gene therapy and gene editing hold promise for transformative treatment, aiming to mitigate SCD's substantial clinical and economic impact in the coming decade. (Albany, USA) DelveInsight's ' Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast-2034 ' report delivers an in-depth understanding of Sickle Cell Disease, historical and forecasted epidemiology as well as the Sickle Cell Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Sickle Cell Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Sickle Cell Disease market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Sickle Cell Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Sickle Cell Disease market. Some facts of the Sickle Cell Disease Market Report are: According to DelveInsight, Sickle Cell Disease market size is expected to grow at a decent CAGR by 2034. Leading Sickle Cell Disease companies working in the market are Cellectis, Sana Biotechnology, Global Blood Therapeutics, Inc., CSL Behring, Pfizer, Aruvant Sciences, Graphite Bio, Novartis, Agios Pharmaceuticals, Forma therapeutics, Vertex Pharmaceuticals, Global Blood Therapeutics, Inc., Alfasigma, Novo Nordisk, bluebird bio, ExCellThera, Gamida Cell, KM Biologics/Takeda, Editas Medicine, and others. Key Sickle Cell Disease Therapies expected to launch in the market are BPX-501 T cells, Canakinumab, EPI01, CTX001, ADAKVEO, DROXIA, ENDARI, OXBRYTA, and many others. In May 2025, Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company specializing in precision genetic medicines via base editing, announced it will share new findings from its BEACON Phase 1/2 clinical trial of BEAM-101 at the upcoming European Hematology Association 2025 Congress (EHA2025), scheduled for June 12–15, 2025, in Milan, Italy. BEAM-101 is an investigational ex vivo genetically modified cell therapy being developed to treat sickle cell disease (SCD), specifically in patients experiencing severe vaso-occlusive crises (VOCs). In November 2024, BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial-stage biopharmaceutical company focused on oncology and rare diseases, announced that an abstract featuring initial results from a Phase 1 trial of motixafortide—both as a monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization in gene therapies for sickle cell disease (SCD)—has been accepted for oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 7-10, 2024, in San Diego, California. Conducted in collaboration with Washington University School of Medicine in St. Louis, this proof-of-concept study aims to explore alternative HSC mobilization approaches to enhance the treatment experience for SCD patients undergoing gene therapy. In May 2024, Afimmune announced results of an Open-label Mechanistic Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients With Sickle Cell Disease In April 2024, Pfizer announced results of an Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants With Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial In April 2024, Novo Nordisk A/S (Forma Therapeutics, Inc.) announced results of an adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS). In July 2023, Novartis announced results of an Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study. Sickle Cell Disease Overview Sickle cell disease (SCD) is a hereditary blood disorder characterized by the production of abnormal hemoglobin, known as hemoglobin S. This defect causes red blood cells to assume a rigid, sickle-like shape, which impedes their ability to flow smoothly through blood vessels. Consequently, these misshapen cells can obstruct blood flow, leading to severe pain, organ damage, and an increased risk of infection. Sickle cell disease is most prevalent among individuals of African, Mediterranean, Middle Eastern, and Indian ancestry. Symptoms typically appear in early childhood and include episodes of pain (called sickle cell crises), chronic anemia, fatigue, swelling in the hands and feet, and delayed growth. Complications can be severe, including stroke, acute chest syndrome, and organ failure. Management of Sickle cell disease involves both preventive and therapeutic strategies. Preventive measures include regular vaccinations, antibiotics to prevent infections, and hydroxyurea, a medication that reduces the frequency of pain crises and the need for blood transfusions. Pain management, blood transfusions, and bone marrow transplants are critical therapeutic options for managing acute and chronic complications. Recent advancements in gene therapy and CRISPR technology hold promise for more effective treatments and potential cures for Sickle cell disease. Ongoing research and clinical trials aim to improve the quality of life for patients and reduce the burden of this debilitating disease. Do you know what will be the Sickle Cell Disease market share in 7MM by 2034 @ Sickle Cell Disease Treatment Market Sickle Cell Disease Market The Sickle Cell Disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Sickle Cell Disease market trends by analyzing the impact of current Sickle Cell Disease therapies on the market and unmet needs, and drivers, barriers, and demand for better technology. This segment gives a thorough detail of the Sickle Cell Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Sickle Cell Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Sickle Cell Disease market in 7MM is expected to witness a major change in the study period 2020-2034. Sickle Cell Disease Epidemiology The Sickle Cell Disease epidemiology section provides insights into the historical and current Sickle Cell Disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Sickle Cell Disease market report also provides the diagnosed patient pool, trends, and assumptions. Interested to know how the emerging diagnostic approaches will be contributing in increased Sickle Cell Disease diagnosed prevalence pool? Download report @ Sickle Cell Disease Market Dynamics and Trends Sickle Cell Disease Drugs Uptake This section focuses on the uptake rate of the potential Sickle Cell Disease drugs recently launched in the Sickle Cell Disease market or expected to be launched in 2020-2034. The analysis covers the Sickle Cell Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Sickle Cell Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Sickle Cell Disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Sickle Cell Disease Pipeline Development Activities The Sickle Cell Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Sickle Cell Disease key players involved in developing targeted therapeutics. Download report to know which TOP 3 therapies will be capturing the largest Sickle Cell Disease market share by 2034? Click here @ Sickle Cell Disease Companies and Medication Sickle Cell Disease Therapeutics Assessment Major key companies are working proactively in the Sickle Cell Disease Therapeutics market to develop novel therapies which will drive the Sickle Cell Disease treatment markets in the upcoming years are Cellectis, Sana Biotechnology, Global Blood Therapeutics, Inc., CSL Behring, Pfizer, Aruvant Sciences, Graphite Bio, Novartis, Agios Pharmaceuticals, Forma therapeutics, Vertex Pharmaceuticals, Global Blood Therapeutics, Inc., Alfasigma, Novo Nordisk, bluebird bio, ExCellThera, Gamida Cell, KM Biologics/Takeda, Editas Medicine, and others. Do you know how market launches of New drugs will be impacting the Sickle Cell Disease market CAGR? Download sample report @ Sickle Cell Disease Therapies and Clinical Trials Sickle Cell Disease Report Key Insights 1. Sickle Cell Disease Patient Population 2. Sickle Cell Disease Market Size and Trends 3. Key Cross Competition in the Sickle Cell Disease Market 4. Sickle Cell Disease Market Dynamics (Key Drivers and Barriers) 5. Sickle Cell Disease Market Opportunities 6. Sickle Cell Disease Therapeutic Approaches 7. Sickle Cell Disease Pipeline Analysis 8. Sickle Cell Disease Current Treatment Practices/Algorithm 9. Impact of Emerging Therapies on the Sickle Cell Disease Market Table of Contents 1. Key Insights 2. Executive Summary 3. Sickle Cell Disease Competitive Intelligence Analysis 4. Sickle Cell Disease Market Overview at a Glance 5. Sickle Cell Disease Disease Background and Overview 6. Sickle Cell Disease Patient Journey 7. Sickle Cell Disease Epidemiology and Patient Population 8. Sickle Cell Disease Treatment Algorithm, Current Treatment, and Medical Practices 9. Sickle Cell Disease Unmet Needs 10. Key Endpoints of Sickle Cell Disease Treatment 11. Sickle Cell Disease Marketed Products 12. Sickle Cell Disease Emerging Therapies 13. Sickle Cell Disease Seven Major Market Analysis 14. Attribute Analysis 15. Sickle Cell Disease Market Outlook (7 major markets) 16. Sickle Cell Disease Access and Reimbursement Overview 17. KOL Views on the Sickle Cell Disease Market 18. Sickle Cell Disease Market Drivers 19. Sickle Cell Disease Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer About DelveInsight DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Health Line
19-06-2025
- Health
- Health Line
Your FAQs Answered: How Does Beta Thalassemia Affect Your Blood?
Beta thalassemia is a blood condition that causes low levels of functional red blood cells, which may sometimes cause mild to severe anemia. Beta thalassemia results from mutations in the HBB gene, which gives your body instructions for producing hemoglobin, a protein in red blood cells that carries oxygen. This leads to abnormal hemoglobin and defective red blood cells. Beta thalassemia may cause mild to severe anemia, depending on the specific form of your condition. Severe anemia can cause life-threatening complications without treatment. Read on to find the answers to your most pressing questions about beta thalassemia. How does beta thalassemia affect the blood? If you have beta thalassemia, your body produces fewer red blood cells than usual. Your red blood cells are also smaller than usual and may not contain enough functional hemoglobin. Hemoglobin in red blood cells carries oxygen around your body, which your cells need to function properly. When you don't have enough red blood cells with functional hemoglobin, your cells don't get enough oxygen. This is known as anemia. The condition can lead to tissue and organ damage. Beta thalassemia may cause mild to severe anemia. How serious is beta thalassemia? There are three main forms of beta thalassemia, which range from mild to severe: Beta thalassemia minor: This form of the condition may cause mild anemia. Beta thalassemia intermediate: This form can cause mild to moderately severe anemia. Beta thalassemia major: This form causes severe anemia, which can lead to potentially life-threatening complications without treatment. If you inherit a mutation of the HBB gene from one parent, you'll develop beta thalassemia minor, also known as beta thalassemia trait. Most people with beta thalassemia trait never know they have it and don't require treatment. If you inherit mutations of the HBB gene from both parents, you'll develop beta thalassemia intermediate or beta thalassemia major. Beta thalassemia major typically causes severe anemia within the first 2 years of life. To treat severe anemia, your doctor will most likely prescribe blood transfusions. People with beta thalassemia major often require regular blood transfusions to survive. People with beta thalassemia intermediate may require occasional blood transfusions. Multiple blood transfusions can lead to hemochromatosis (iron overload), damaging your tissues and organs. Beta thalassemia can also contribute to iron overload by causing your body to absorb more iron than usual from food in your digestive tract. Your doctor will prescribe iron-lowering medication to treat iron overload. This is known as iron chelation therapy. What are the potential complications of beta thalassemia? Severe anemia from beta thalassemia can cause complications, such as: delay in growth and puberty in adolescents or preadolescents sexual maturation delay enlarged spleen or liver atypical bone marrow expansion, which may cause brittle bones and structural changes in the bones unusual masses in your spleen, liver, lymph nodes, chest, or spine Iron overload from beta thalassemia or blood transfusions can also cause complications, such as damage to the: heart, which may cause inflammation, atypical heart rhythms, and heart failure liver, which may cause inflammation, scarring known as cirrhosis, and liver failure endocrine glands, which may cause thyroid disease or, in rare cases, diabetes Some of these complications are potentially life threatening. The red blood cells in beta thalassemia are more likely to stick to each other, which increases the risk of blood clots in veins, known as venous thrombosis. Following a recommended treatment plan can lower your risk of complications. Does beta thalassemia affect the immune system? Beta thalassemia can affect your spleen, which is important to your immune system. The spleen is an organ in your abdomen that helps control your level of blood cells. It also filters your blood and monitors it for certain infections. Anemia from beta thalassemia may require your spleen to work harder than usual to produce red blood cells. As a result, it may not be able to filter your blood as well as it did before. This increases the risk of certain infections. Can beta thalassemia turn into leukemia? A 2019 research review showed that experts need more research to learn how beta thalassemia and other forms of thalassemia affect the risk of cancers. Evidence suggests that people with the intermediate or major form of beta thalassemia have an increased risk of blood cancers, including lymphoma and leukemia. Iron overload from regular blood transfusions or beta thalassemia may help account for the increased cancer risk. Too much iron in your body can damage cells and increase the risk of cellular mutations. Bloodborne viruses that raise the risk of certain cancers may also be transmissible to people through blood transfusions. The United States requires donor blood to get tests for some, but not all, types of viruses. Beta thalassemia can also cause changes to your blood marrow, which might affect cancer risk. How does beta thalassemia compare with alpha thalassemia? Alpha thalassemia is another blood condition that causes low levels of functional hemoglobin. Alpha and beta thalassemia affect different parts of the hemoglobin protein. Both conditions can cause anemia ranging from mild to severe, which may require blood transfusions to treat. The most severe form of alpha thalassemia usually leads to death in newborns. Takeaway Beta thalassemia is a blood condition that causes low levels of functional hemoglobin. Beta thalassemia minor often causes no symptoms and requires no treatment. Beta thalassemia intermediate may cause mild to moderately severe anemia, which may require occasional blood transfusions to treat. Beta thalassemia causes severe anemia, which often requires regular blood transfusions to prevent and treat.
